For the treatment of chronic asymptomatic hepatitis B carriers. Some doctors believe that “virus carriers do not need special treatment, and that it is impossible to turn all the indicators of hepatitis B patients negative from the current level of medical science”. It is also said that “for hepatitis B virus carriers, the immune system is in a state of immune tolerance, and there is no immune elimination activity in the liver. Therefore, it is not the right time to use antiviral therapy, so hepatitis B virus carriers should be tested regularly (3-6 months) for liver function, serological and virological indicators and ultrasound, etc. to dynamically observe the changes. As long as the liver function is normal, there is no need for drug treatment”. This view has some truth. Because more than a decade ago. Because of the lack of understanding of the hepatitis B virus and the lack of effective methods of treatment, most medical doctors advocate regular testing of chronic asymptomatic hepatitis B carriers, dynamic observation and standby treatment. But now it seems that it is an old and backward view. Due to the development of medicine, people’s views have changed significantly in recent years. Most medical doctors believe that asymptomatic hepatitis B virus carriers (chronic asymptomatic hepatitis B carriers in the tolerance period) have no clinical symptoms, but the liver has already undergone pathological changes, which will definitely endanger the liver health in the long run and should be treated reasonably. In fact, the majority of clinically diagnosed chronic asymptomatic hepatitis B carriers are already hepatitis, a few are already early cirrhosis, and some are liver cancer. Our medical practice proves that for chronic asymptomatic hepatitis B carriers in immune tolerance, most of them can break the immune tolerance with immune modulation, and with antiviral therapy and Chinese medicine, they can achieve better results in terms of HBV-DNA or e antigen conversion, and a small number of patients also have a full conversion. For patients with chronic asymptomatic hepatitis B carriers who are recovering from viral residues, the focus of treatment is to enhance the body’s immune system to promote the further removal of HBV, and to strive for the conversion of HBsAg to negative and the production of anti-HBs. For patients aged 40 years or older, especially those aged 60 years or older with viral residues of “small triplets”, the goal of treatment is also to To prevent the development of hepatocellular carcinoma. It is important to note that the treatment of hepatitis B virus carriers should not be expected to be “quick and easy” or to “turn negative”, but to stop the progression of hepatitis B disease and prevent it from developing into hepatitis or cirrhosis. The “conversion” is only one aspect of treatment and does not represent the full picture of the pathological changes in the liver. The view of treatment and the view of observation are two very different views. The correct viewpoint, which is relevant to current medical practice, should be active treatment. Clinically, our principle is that for hepatitis B virus-infected patients under 10 years of age, if there are no abnormal findings in liver function and ultrasound, dynamic observation is generally not required for treatment. In other age groups, regardless of “major and minor triple-positive”, they should be examined and treated. For so-called chronic asymptomatic hepatitis B carriers over 35 years old, they should be considered for chronic hepatitis or early cirrhosis, and should be actively treated, checked for positive hepatitis B virus, and have regular ultrasound or liver aspiration to prevent the development or deterioration of the disease.